UPDATE: Piper Jaffray Raises Price Target on Trius Therapeutics to $15
According to Piper Jaffray, Trius Therapeutics (NASDAQ: TSRX) price target is raised to $15.
Piper Jaffray said that following positive results from the 1st pivotal tedizolid trial, Trius is a Top Pick for 2012. “We reiterate our Overweight rating and are increasing our price target to $15 from $12.”
Trius Therapeutics closed on Friday at $7.15.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.